Literature DB >> 1650694

The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.

D Felmingham1, M J Robbins, M Sanghrajka, A Leakey, G L Ridgway.   

Abstract

Erythromycin is a macrolide antimicrobial chemically comprised of a 14-membered lactone ring substituted with a neutral (cladinose) and an amino (desosamine) sugar. Recently, a number of new macrolide molecules have been identified containing either 14-, 15- or 16-membered substituted lactone rings. In this study the authors have determined the in vitro activity of roxithromycin and clarithromycin (both 14-membered macrolides), azithromycin (a 15-membered macrolide or azalide) and midecamycin acetate (a 16-membered macrolide) against clinical isolates of Staphylococcus spp., (including methicillin-susceptible and -resistant isolates), Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Minimum inhibitory concentrations of the macrolides for the clinical isolates of Staphylococcus spp. examined were widely distributed. However, midecamycin acetate retained activity against those isolates of Staphylococcus spp. exhibiting inducible resistance to erythromycin and the other macrolides tested. Isolates characterised by constitutive resistance to erythromycin were also resistant to midecamycin acetate. All of the macrolides were very active against Legionella spp., with clarithromycin demonstrating the greatest potency (MIC range: less than or equal to 0.03-0.06 mg/l). Isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum were susceptible to all of the macrolides tested. However, erythromycin, roxithromycin, clarithromycin and azithromycin were poorly active against isolates of Mycoplasma hominis. By contrast, the same isolates were susceptible (MIC range: 0.008-0.12 mg/l) to midecamycin acetate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650694

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  9 in total

Review 1.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

2.  Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study.

Authors:  S Schönwald; I Kuzman; K Oresković; V Burek; V Skerk; V Car; D Bozinović; J Culig; S Radosević
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

3.  Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.

Authors:  K M Olsen; G San Pedro; L P Gann; P O Gubbins; D M Halinski; G D Campbell
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  Macrolide susceptibility of Mycoplasma hyorhinis isolated from piglets.

Authors:  H Kobayashi; T Morozumi; G Munthali; K Mitani; N Ito; K Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 6.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 7.  Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  S M Holliday; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

9.  Azithromycin (zithromax).

Authors:  J M McCarty
Journal:  Infect Dis Obstet Gynecol       Date:  1996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.